Gut Microbiota Dysbiosis and Translocation During IBD and Parkinson

Study Overview
=================
Brief Summary
-----------------
Inflammatory bowel diseases (IBD) and Parkinson disease (PD) are complex and multifactorial pathologies. Gut microbiota seems to play an active role. Indeed the digestive microbiota of patients with IBD or PD exhibits different compositions compared with asymptomatic subjects. Bacterial translocation from gut to blood has been reported.

Detailed Description
-----------------
The investigators designed a case-control study to investigate the digestive microbiota and bacterial translocation during IBD and PD. The investigators want to evaluate gut microbiota bacteria involved in dysbiosis and bacterial translocation during IBD and PD. The investigators want to identify bacterial populations that can serve as biomarkers for clinical practice.

Official Title
-----------------
Gut Microbiota Dysbiosis and Translocation Within Patients Suffering From Diseases Associated With Increased Intestinal Barrier Permeability : IBD and Parkinson

Conditions
-----------------
Inflammatory Bowel Diseases, Parkinson Disease

Intervention / Treatment
-----------------
* Other: stool and blood analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: PD patients : age < or = 60 years asymptomatic subjects : no chronic disease asymptomatic subjects : no treatment Exclusion Criteria: severe anemia (Hb<7g/L) people who don't read french pregnant women people treated by antibiotic, probiotic or prebiotic during the 2 month before inclusion people with any diagnosed or treated pathology

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: IBD or PD patients<br>20 patients suffering from IBD 10 patients suffering from PD | Other: stool and blood analysis<br>* High throughput sequencing and quantitative PCR<br>|
| Active Comparator: Asymptomatic subjects<br>30 asymptomatic subjects matched to patients on age, sexe and BMI | Other: stool and blood analysis<br>* High throughput sequencing and quantitative PCR<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 16S RNA sequencing in stool sample | 16S RNA sequencing to identify species constituting the microbiota in the stool | 2 years | 
| 16S RNA sequencing in blood sample | 16S RNA sequencing to identify species constituting the microbiota in the blood | 2 years | 
| Stool quantification of key bacteria associated with intestinal barrier permeability. | To determine stool rates of Faecalibacterium prausnitzii, Akkermansia muciniphila, Bacteroides fragilis, Clostridium difficile, Mycobacterium avium paratuberculosis and Escherischia coli by qPCR | 2 years | 
| Blood quantification of key bacteria associated with intestinal barrier permeability. | To determine blood rates of Faecalibacterium prausnitzii, Akkermansia muciniphila, Bacteroides fragilis, Clostridium difficile, Mycobacterium avium paratuberculosis and Escherischia coli by qPCR | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
gut microbiota, Bacterial translocation